paroxetine has been researched along with vn2222 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosch, A; Del Castillo, JC; Del Río, J; Heras, B; Lasheras, B; Martínez-Esparza, J; Monge, A; Mourelle, M; Oficialdegui, AM; Orús, L; Palop, JA; Pérez-Silanes, S; Roca, J; Tordera, R | 1 |
1 other study(ies) available for paroxetine and vn2222
| Article | Year |
|---|---|
New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Carrier Proteins; Colony-Forming Units Assay; Conditioning, Operant; Cyclic AMP; HeLa Cells; Humans; Hypothermia; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Nerve Tissue Proteins; Piperazines; Radioligand Assay; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Thiophenes | 2001 |